Key result
Detectable circulating FXIa linked to ~38-fold higher risk of recurrent VTE after PE.
Why the study?
Detectable circulating activated factor XI (FXIa) predisposes to atherothromboembolism and venous thrombosis, but its prognostic value for recurrent venous thromboembolism in patients following pulmonary embolism was unknown.
Does detectable circulating activated factor XI (FXIa) predict recurrent venous thromboembolism in noncancer patients aged 18 to 64 years following pulmonary embolism?
Cohort (n=198)
Does detectable circulating activated factor XI (FXIa) predict recurrent venous thromboembolism in noncancer patients aged 18 to 64 years following pulmonary embolism?
Answers are grounded in this paper and cite their sources.
Detectable circulating activated factor XI (FXIa) is a strong independent predictor of recurrent venous thromboembolism in patients following pulmonary embolism, irrespective of anticoagulation status or type.
Background Venous thromboembolism (VTE) carries a substantial risk of recurrence, estimated at 1-5% of patients within one year despite guideline-recommended management. Detectable activated factor XI (FXIa) in circulating blood, as demonstrated previously1, predisposes to atherothromboembolism and venous thrombosis; however, the prognostic value of FXIa in patients following pulmonary embolism (PE) is unknown. Purpose We investigated whether detectable circulating FXIa is associated with VTE recurrence in patients following PE. Methods This prospective cohort study included 198 white noncancer patients aged 18 to 64 years who were receiving anticoagulation for at least 3 months following documented PE (with or without concomitant deep vein thrombosis). Baseline FXIa was quantified by measuring clotting time in the presence of the inhibitory monoclonal antibody anti-FXIa2. Symptomatic recurrent VTE and major bleeding were recorded during a median follow-up of 83 (IQR 76-90) months. Results FXIa was detectable in 41 (20.7%) patients at enrollment and did not correlate with demographic or clinical parameters. During follow-up, VTE recurred in 34 PE patients (17.2%; 2.5% per year), including 9 individuals who stopped anticoagulation. Patients with and without recurrent VTE were similar with regard to demographic, clinical, and laboratory variables, including anticoagulant type and cessation (Table 1). Detectable FXIa was 11.7-fold more prevalent in PE patients with recurrent VTE compared with the remainder (85.3% vs 7.3%, p<0.001; Table 1, Figure 1). At a time horizon (τ) of 96 months, equivalent to the 90th centile of follow-up duration3, the difference in restricted mean survival time was 34.1 months (bootstrapped 95% confidence interval [CI]: 24.1-43.6, p<0.001), reflecting 1.6-fold longer event-free survival in patients without circulating FXIa. After adjustment for age, unprovoked VTE, and number of prior VTE events, FXIa was independently associated with VTE recurrence (hazard ratio [HR]: 38.0, 95% CI: 15.3-120.2, p<0.001). The incidence of major bleeding during follow-up was not affected by detectable FXIa (Table 1). Conclusion We have shown that FXIa can help identify PE patients at risk of recurrent VTE, irrespective of anticoagulation status or type. Detectable circulating FXIa may encapsulate residual prothrombotic risk in this patient group. Given promising outcomes of FXI/FXIa inhibitors in primary prevention of VTE, it is tempting to suggest that these agents could be used in PE patients with activated FXI.
No takes yet. Share an insight, caveat, or question.
Michel et al. (2026) conducted a cohort in Pulmonary embolism (PE) (n=198). Detectable circulating activated factor XI (FXIa) vs. Undetectable circulating activated factor XI (FXIa) was evaluated on Symptomatic recurrent venous thromboembolism (VTE) (HR 38.0, 95% CI 15.3-120.2, p=<0.001). Detectable circulating FXIa was independently associated with symptomatic recurrent VTE in patients following PE.
Synapse has enriched 10 related papers. Consider them for comparative context: